Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Elevated Myonuclear Density During Skeletal Muscle Hypertrophy In Response to Training Is Reversed During Detraining.

Dungan CM, Murach KA, Frick KK, Jones SR, Crow SE, Englund DA, Vechetti IJ Jr, Figueiredo VC, Levitan BM, Satin J, McCarthy JJ, Peterson CA.

Am J Physiol Cell Physiol. 2019 Mar 6. doi: 10.1152/ajpcell.00050.2019. [Epub ahead of print]

PMID:
30840493
2.

Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review.

van Overbeeke E, Whichello C, Janssens R, Veldwijk J, Cleemput I, Simoens S, Juhaeri J, Levitan B, Kübler J, de Bekker-Grob E, Huys I.

Drug Discov Today. 2019 Jan;24(1):57-68. doi: 10.1016/j.drudis.2018.09.015. Epub 2018 Sep 26. Review.

3.

Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.

Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberté F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

Chest. 2018 Dec;154(6):1371-1378. doi: 10.1016/j.chest.2018.08.1059. Epub 2018 Sep 7.

4.

Development of a Gill Assay Library for Ecological Proteomics of Threespine Sticklebacks (Gasterosteus aculeatus).

Li J, Levitan B, Gomez-Jimenez S, Kültz D.

Mol Cell Proteomics. 2018 Nov;17(11):2146-2163. doi: 10.1074/mcp.RA118.000973. Epub 2018 Aug 9.

5.

Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.

Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Cohen AT, Davidson BL, van Bellen B, Verhamme P, Wells PS, Yuan Z, Levitan B, Weitz JI.

Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10.

PMID:
30064683
6.

Azithromycin therapy reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction: Potential therapeutic targets in ischemic heart disease.

Al-Darraji A, Haydar D, Chelvarajan L, Tripathi H, Levitan B, Gao E, Venditto VJ, Gensel JC, Feola DJ, Abdel-Latif A.

PLoS One. 2018 Jul 12;13(7):e0200474. doi: 10.1371/journal.pone.0200474. eCollection 2018.

7.

Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.

Gibson CM, Levitan B, Gibson WJ, Yee MK, Murphy SA, Yuan Z, Chakrabarti AK, Lee M, Braunwald E.

J Am Coll Cardiol. 2018 Jul 10;72(2):129-136. doi: 10.1016/j.jacc.2018.04.055.

PMID:
29976285
8.

Symposium Title: Preference Evidence for Regulatory Decisions.

Gonzalez JM, Johnson FR, Levitan B, Noel R, Peay H.

Patient. 2018 Oct;11(5):467-473. doi: 10.1007/s40271-018-0311-y. No abstract available.

PMID:
29845480
9.

Rad GTPase deletion attenuates post-ischemic cardiac dysfunction and remodeling.

Manning JR, Chelvarajan L, Levitan BM, Withers CN, Nagareddy PR, Haggerty CM, Fornwalt BK, Gao E, Tripathi H, Abdel-Latif A, Andres DA, Satin J.

JACC Basic Transl Sci. 2018 Feb;3(1):83-96. doi: 10.1016/j.jacbts.2017.09.004.

10.

Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project.

Levitan B, Getz K, Eisenstein EL, Goldberg M, Harker M, Hesterlee S, Patrick-Lake B, Roberts JN, DiMasi J.

Ther Innov Regul Sci. 2018 Mar;52(2):220-229. doi: 10.1177/2168479017716715. Epub 2017 Jul 17.

11.

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.

Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP.

Int J Cardiol. 2018 Apr 15;257:78-83. doi: 10.1016/j.ijcard.2017.06.110.

PMID:
29506743
12.

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.

Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberté F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

J Med Econ. 2018 Jun;21(6):587-594. doi: 10.1080/13696998.2018.1444615. Epub 2018 Mar 16.

PMID:
29469638
13.

Quality of care and patient-reported outcomes in carpal tunnel syndrome: A prospective observational study.

Nuckols TK, Conlon C, Robbins M, Dworsky M, Lai J, Roth CP, Levitan B, Seabury S, Seelam R, Benner D, Asch SM.

Muscle Nerve. 2018 Jun;57(6):896-904. doi: 10.1002/mus.26041. Epub 2018 Feb 1.

PMID:
29272038
14.

The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States.

Levitan B, Hauber AB, Damiano MG, Jaffe R, Christopher S.

Patient. 2017 Oct;10(5):531-536. doi: 10.1007/s40271-017-0272-6. No abstract available.

PMID:
28831745
15.

Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project.

de Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, Pelouchova J, Enzmann H, Cook N, Hansson MG.

Patient. 2017 Jun;10(3):263-266. doi: 10.1007/s40271-017-0222-3. No abstract available.

PMID:
28247251
16.

Quality of Care for Work-Associated Carpal Tunnel Syndrome.

Nuckols T, Conlon C, Robbins M, Dworsky M, Lai J, Roth CP, Levitan B, Seabury S, Seelam R, Asch SM.

J Occup Environ Med. 2017 Jan;59(1):47-53. doi: 10.1097/JOM.0000000000000916.

17.

Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.

Katz EG, Hauber B, Gopal S, Fairchild A, Pugh A, Weinstein RB, Levitan BS.

Patient Prefer Adherence. 2016 Oct 21;10:2127-2139. eCollection 2016.

18.

Rad-deletion Phenocopies Tonic Sympathetic Stimulation of the Heart.

Levitan BM, Manning JR, Withers CN, Smith JD, Shaw RM, Andres DA, Sorrell VL, Satin J.

J Cardiovasc Transl Res. 2016 Dec;9(5-6):432-444. Epub 2016 Oct 31.

19.

Assessing the Value of High-Quality Care for Work-Associated Carpal Tunnel Syndrome in a Large Integrated Health Care System: Study Design.

Conlon C, Asch S, Hanson M, Avins A, Levitan B, Roth C, Robbins M, Dworsky M, Seabury S, Nuckols T.

Perm J. 2016 Fall;20(4):15-220. doi: 10.7812/TPP/15-220. Epub 2016 Oct 3.

20.

A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies.

Ho M, Saha A, McCleary KK, Levitan B, Christopher S, Zandlo K, Braithwaite RS, Hauber AB; Medical Device Innovation Consortium’s Patient Centered Benefit-Risk Steering Committee.

Value Health. 2016 Sep - Oct;19(6):746-750. doi: 10.1016/j.jval.2016.02.019.

21.

Patient Engagement at a Tipping Point-The Need for Cultural Change Across Patient, Sponsor, and Regulator Stakeholders: Insights From the DIA Conference, "Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products".

Smith MY, Hammad TA, Metcalf M, Levitan B, Noel R, Wolka AM, Michaels DL, Johnson FR.

Ther Innov Regul Sci. 2016 Sep;50(5):546-553. doi: 10.1177/2168479016662902.

PMID:
30231755
22.

Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.

Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L.

Int Clin Psychopharmacol. 2016 Nov;31(6):315-22. doi: 10.1097/YIC.0000000000000141.

23.

Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.

Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AWA.

Chest. 2016 Nov;150(5):1059-1068. doi: 10.1016/j.chest.2016.05.023. Epub 2016 Jun 1.

PMID:
27262225
24.

Patients' Priorities For Treatment In Severe Asthma.

Whalley D, Hauber AB, Crawford SR, Posner J, Doward L, Levitan B, Hemels M, Valgardsson VS.

Value Health. 2015 Nov;18(7):A504. doi: 10.1016/j.jval.2015.09.1433. Epub 2015 Oct 20. No abstract available.

25.

Patients' Priorities For Treatment In Moderate To Severe Copd.

Whalley D, Hauber AB, Crawford SR, Posner J, Doward L, Levitan B, Hemels M, Valgardsson VS.

Value Health. 2015 Nov;18(7):A503-4. doi: 10.1016/j.jval.2015.09.1432. Epub 2015 Oct 20. No abstract available.

26.

Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.

Radawski C, Morrato E, Hornbuckle K, Bahri P, Smith M, Juhaeri J, Mol P, Levitan B, Huang HY, Coplan P, Li H; BRACE Special Interest Group.

Pharmacoepidemiol Drug Saf. 2015 Dec;24(12):1233-40. doi: 10.1002/pds.3859. Epub 2015 Oct 12. Review.

PMID:
26456379
27.

Loss of Rad-GTPase produces a novel adaptive cardiac phenotype resistant to systolic decline with aging.

Manning JR, Withers CN, Levitan B, Smith JD, Andres DA, Satin J.

Am J Physiol Heart Circ Physiol. 2015 Oct;309(8):H1336-45. doi: 10.1152/ajpheart.00389.2015. Epub 2015 Sep 14.

28.

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions.

Pignatti F, Ashby D, Brass EP, Eichler HG, Frey P, Hillege HL, Hori A, Levitan B, Liberti L, Löfstedt RE, McAuslane N, Micaleff A, Noel RA, Postmus D, Renn O, Sabourin BJ, Salmonson T, Walker S.

Clin Pharmacol Ther. 2015 Nov;98(5):522-33. doi: 10.1002/cpt.203. Epub 2015 Sep 11. Review.

29.

Benefit-Risk Evaluation and Decision Making: Some Practical Insights.

Colopy MW, Damaraju CV, He W, Jiang Q, Levitan BS, Ruan S, Yuan Z.

Ther Innov Regul Sci. 2015 May;49(3):425-433. doi: 10.1177/2168479014565469.

PMID:
30222397
30.

Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation-evidence from the United States and Japan.

Okumura K, Inoue H, Yasaka M, Gonzalez JM, Hauber AB, Levitan B, Yuan Z, Briere JB.

Value Health Reg Issues. 2015 May;6:65-72. doi: 10.1016/j.vhri.2015.03.016. Epub 2015 May 16.

PMID:
29698195
31.

Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia Treatment.

Levitan B, Markowitz M, Mohamed AF, Johnson FR, Alphs L, Citrome L, Bridges JF.

Psychiatr Serv. 2015 Jul;66(7):719-26. doi: 10.1176/appi.ps.201400188. Epub 2015 Mar 16.

PMID:
25772762
32.

Structured Approaches to Benefit-Risk Assessment: A Case Study and the Patient Perspective.

Levitan B, Phillips LD, Walker S.

Ther Innov Regul Sci. 2014 Sep;48(5):564-573. doi: 10.1177/2168479014536500.

PMID:
30231454
33.

Psychiatrists' judgments about antipsychotic benefit and risk outcomes and formulation in schizophrenia treatment.

Markowitz MA, Levitan BS, Mohamed AF, Johnson FR, Bridges JF, Alphs L, Citrome L.

Psychiatr Serv. 2014 Sep 1;65(9):1133-9. doi: 10.1176/appi.ps.201300290.

PMID:
24828964
34.

Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives.

Yuan Z, Levitan B, Burton P, Poulos C, Brett Hauber A, Berlin JA.

Curr Med Res Opin. 2014 Sep;30(9):1733-41. doi: 10.1185/03007995.2014.921611. Epub 2014 Jun 2.

PMID:
24827068
35.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

36.

Circumferential gap propagation in an anisotropic elastic bacterial sacculus.

Taneja S, Levitan BA, Rutenberg AD.

Phys Rev E Stat Nonlin Soft Matter Phys. 2014 Jan;89(1):012704. Epub 2014 Jan 7.

PMID:
24580254
37.

Lean body mass may explain apparent racial differences in carotid intima-media thickness in obese children.

Chowdhury SM, Henshaw MH, Friedman B, Saul JP, Shirali GS, Carter J, Levitan BM, Hulsey T.

J Am Soc Echocardiogr. 2014 May;27(5):561-7. doi: 10.1016/j.echo.2014.01.007. Epub 2014 Feb 8.

38.

Pain qualities and satisfaction with therapy: a survey of subjects with neuropathic pain.

Cepeda MS, Wilcox M, Levitan B.

Pain Med. 2013 Nov;14(11):1745-56. doi: 10.1111/pme.12210. Epub 2013 Jul 24.

39.

Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies.

Markowitz M, Fu DJ, Levitan B, Gopal S, Turkoz I, Alphs L.

Ann Gen Psychiatry. 2013 Jul 11;12(1):22. doi: 10.1186/1744-859X-12-22.

40.

Time course of recovery showing initial prefrontal cortex changes at 16 weeks, extending to subcortical changes by 3 years in pediatric bipolar disorder.

Yang H, Lu LH, Wu M, Stevens M, Wegbreit E, Fitzgerald J, Levitan B, Shankman S, Pavuluri MN.

J Affect Disord. 2013 Sep 5;150(2):571-7. doi: 10.1016/j.jad.2013.02.007. Epub 2013 Mar 18.

41.

Trajectories of health care service utilization and differences in patient characteristics among adults with specific chronic pain: analysis of health plan member claims.

Ruetsch C, Tkacz J, Kardel PG, Howe A, Pai H, Levitan B.

J Pain Res. 2013;6:137-49. doi: 10.2147/JPR.S38301. Epub 2013 Feb 21.

42.

Corrected QT interval as a predictor of mortality in elderly patients with syncope.

Aggarwal A, Sherazi S, Levitan B, Lakshmanadoss U, Choudhary N, Shah A, Hsi D.

Cardiol J. 2011;18(4):395-400.

43.

Benefit-risk assessment: to quantify or not to quantify, that is the question.

Yuan Z, Levitan B, Berlin JA.

Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):653-6. doi: 10.1002/pds.2149. No abstract available.

PMID:
21538675
44.

Right Ventricle Failure in Sepsis: A Case Report.

Lakshmanadoss U, Levitan BM, Hsi DH.

Cardiol Res. 2011 Feb;2(1):48-49. doi: 10.4021/cr12w. Epub 2011 Jan 20.

45.

Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters.

Walker S, Liberti L, McAuslane N, Levitan BS.

Clin Pharmacol Ther. 2011 Feb;89(2):179-82. doi: 10.1038/clpt.2010.290. Erratum in: Clin Pharmacol Ther. 2011 Jun;89(6):928. Clin Pharmacol Ther. 2012 Jan;91(1):150. Levitan, B S [added].

PMID:
21252937
46.

Application of the BRAT framework to case studies: observations and insights.

Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, Coplan PM, Mussen F.

Clin Pharmacol Ther. 2011 Feb;89(2):217-24. doi: 10.1038/clpt.2010.280. Epub 2010 Dec 22.

PMID:
21178990
47.

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.

Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F.

Clin Pharmacol Ther. 2011 Feb;89(2):312-5. doi: 10.1038/clpt.2010.291. Epub 2010 Dec 15. No abstract available.

PMID:
21160469
48.

A concise display of multiple end points for benefit-risk assessment.

Levitan B.

Clin Pharmacol Ther. 2011 Jan;89(1):56-9. doi: 10.1038/clpt.2010.251. Epub 2010 Nov 24. Erratum in: Clin Pharmacol Ther. 2011 Mar;89(3):468.

PMID:
21107317
49.

A model for decision support in signal triage.

Levitan B, Yee CL, Russo L, Bayney R, Thomas AP, Klincewicz SL.

Drug Saf. 2008;31(9):727-35.

PMID:
18707187
50.

[Level of natural autoantibodies to interferon-alpha and characteristics of interferon status during chronic hepatitis and liver cirrhosis].

Astakhin AV, Efimova EE, Zverev VV, Levitan BN, Afanas'ev SS, Nesvizhskiĭ IuV, Aleshkin VA, Larina NN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):65-8. Russian.

PMID:
17886379

Supplemental Content

Loading ...
Support Center